Both in Biotechnology
Inhibikase Therapeutics vs ProKidney
Over the past year IKT returned −1.6% and PROK returned −60.0%; their daily moves had a correlation of 0.27.
IKT −1.6% PROK −60.0%Growth of $1, one year, split-adjusted
| Metric | IKT | PROK |
|---|---|---|
| Price | $1.57 | $1.12 |
| Market cap | $218.4M | $234.1M |
| Today | +5.74% | +4.67% |
| 1 month | −21.0% | −30.0% |
| 6 months | −22.1% | −42.9% |
| Year to date | −23.7% | −50.0% |
| 1 year | −2.2% | −60.7% |
| Revenue growth (YoY) | — | −32.1% |
| Gross margin | — | 100.0% |
| Net margin | — | −18948.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 286.1× |
| Net cash | $159.0M | $181.6M |
| Dividend yield | — | — |
| Volatility (60d) | 52.6% | 85.6% |
| Short % of float | 17.8% | 27.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).